Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR3C2 | P08235 | 5/20 | 0.73 |
| ▸ | PDE7A | Q13946 | 2/20 | 0.37 |
| ▸ | IDH1 | O75874 | 1/20 | 0.37 |
| ▸ | PTGES | O14684 | 1/20 | 0.36 |
| ▸ | AVPR2 | P30518 | 2/20 | 0.36 |
| ▸ | GPR27 | Q9NS67 | 2/20 | 0.36 |
| ▸ | KIT | P10721 | 1/20 | 0.35 |
| ▸ | ELANE | P08246 | 4/20 | 0.35 |
| ▸ | PDE4A | P27815 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
| ▸ | TRPV4 | Q9HBA0 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18593496 | 0.90 | NR3C2 (0.77) | NR3C2PDE7APTGESAVPR2GPR27 | |
| SCHEMBL29571805 | 0.84 | NR3C2 (1.00) | NR3C2PDE7APTGESAVPR2GPR27 | |
| SCHEMBL1381714 | 0.84 | NR3C2 (1.00) | NR3C2PDE7APTGESAVPR2GPR27 | |
| SCHEMBL1380377 | 0.84 | NR3C2 (0.67) | NR3C2PDE7AAVPR2GPR27PDE4A | |
| SCHEMBL19206629 | 0.82 | NR3C2 (0.71) | NR3C2IDH1ELANELMNAPOLB | |
| SCHEMBL2438254 | 0.80 | NR3C2 (0.75) | NR3C2AVPR2GPR27LMNAPOLB | |
| SCHEMBL1378883 | 0.79 | NR3C2 (0.90) | NR3C2PDE7APTGESAVPR2GPR27 | |
| SCHEMBL19775750 | 0.79 | NR3C2 (0.67) | NR3C2PDE7AIDH1AVPR2GPR27 | |
| SCHEMBL1383401 | 0.79 | NR3C2 (0.78) | NR3C2PDE7AAVPR2GPR27PDE4A | |
| SCHEMBL1380002 | 0.79 | NR3C2 (0.88) | NR3C2PDE7APTGESAVPR2GPR27 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190175551-A1 | MEDICINE FOR TREATING RENAL DISEASE | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2019-06-13 | — | — | US | disclosed |
| US-10005725-B2 | Method for producing pyrrole derivative, and intermediate thereof | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2018-06-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190175551-A1 | MEDICINE FOR TREATING RENAL DISEASE | REN, NR3C2, ATP6V1B1 | NR3C2 2/4885PDE7A 1204/4885IDH1 3647/4885 |
| US-10005725-B2 | Method for producing pyrrole derivative, and intermediate thereof | NR3C2, MC2R, CYP11B2 | NR3C2 1/4885PDE7A 586/4885IDH1 2140/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.